Navigation Links
Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008
Date:7/29/2008

otal sales guidance is increased by $30 million to $1.86 - $1.91 billion. This includes CNS franchise sales of $975 - $1,000 million, pain franchise sales of $500 - $525 million, oncology franchise sales of $155 - $180 million, and other product sales of $200 - $225 million. Full year SG&A and R&D guidance is $770 - $790 million and $340 - $360 million, respectively, and reflects a $30 million increase in SG&A guidance. Adjusted net income guidance for 2008 is $346 - $353 million and basic adjusted income per common share guidance is $5.10 - $5.20.

For the third quarter of 2008, Cephalon is introducing sales guidance of $480 - $490 million, adjusted net income guidance of $85 - $92 million and basic adjusted income per common share guidance of $1.25 - $1.35.

Basic adjusted income per common share guidance for both the third quarter 2008 and full-year 2008 is reconciled below and is subject to the assumptions set forth therein.

Cephalon's management will discuss the company's second quarter 2008 performance in a conference call with investors beginning at 5:00 p.m. U.S. EDT today. To participate in the conference call, dial +1-913-312-9303 and refer to conference code number 6640353. Investors can listen to the call live by logging on to the company's website at http://www.cephalon.com and clicking on "Investor Information," then "Webcast." The conference call will be archived and available to investors for one week after the call.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania,
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains ... these latent viruses is the Epstein Barr Virus (EBV), and ... (RA) is a chronic inflammatory disease that destroys the body’s ... RA patients have high concentrations of EBV DNA in their ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... ALTO, Calif., Dec. 2 Intradigm Corporation, a ... today,announced the issuance of United States patent 7,459,547, ... Silencing." The issued,patent, which is based on ... Stone Cook Chair of Biomedical Sciences and Professor ...
... 2 Cardiogenesis Corporation (Pink Sheets: CGCP), a leading developer ... from severe angina, today announced the addition of veteran medical ... Cohen as a member of the Company,s Board of Directors, ... , Mr. Cohen, 49, has over ...
... ENDO ), an innovative medical device ... used by urologists and,interventional radiologists for tissue and ... institutions including Mayo Clinic,Memorial Sloan-Kettering Cancer Center and ... among others, will present a total of 38 ...
Cached Biology Technology:Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics 2Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics 3Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors 2Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors 338 Cryoablation Studies, Exhibits Presented at National Radiological Society Meeting 238 Cryoablation Studies, Exhibits Presented at National Radiological Society Meeting 338 Cryoablation Studies, Exhibits Presented at National Radiological Society Meeting 4
(Date:4/24/2014)... RICHLAND, Wash. A common plant puts out a welcome ... the mat,s molecular mix. , The study published this week ... reveals new targets during the battle between microbe and ... team showed that the humble and oft-studied plant Arabidopsis ... from a pathogen. It,s as if a hostile army were ...
(Date:4/23/2014)... may contribute to early fetal death according to a ... of Children,s Hospital Los Angeles and Ulaanbaatar, Mongolia ... a paper published today in the journal BMC ... correlations" between seasonal ambient air pollutants and pregnancy loss ... of the highest levels of air pollution of all ...
(Date:4/23/2014)... disease, most in their mid-thirties and forties, face ... decline within two decades. "Mutant" protein clusters, long ... have been the primary focus of therapies in ... research from Prof. Gerardo Lederkremer and Dr. Julia ... Research and Immunology, in collaboration with Prof. Ulrich ...
Breaking Biology News(10 mins):How a plant beckons the bacteria that will do it harm 2How a plant beckons the bacteria that will do it harm 3Pollutants from coal-burning stoves strongly associated with miscarriages in Mongolia 2On the defensive 2On the defensive 3
... insight into genetic basis of human diseaseHigh-throughput sequencing of ... which can give clues to the genetic underpinning of ... information from the individual's two chromosomes. Yet many ... individuals' DNA at the level of each chromosome -- ...
... Prehistoric big game hunters and not the last ice age ... sloths and other North American great mammals such as mammoths, ... , Determining whether the first arrival of humans or the ... last Ice Age was responsible for the demise of prehistoric ...
... The National Programme on Substance Abuse Deaths (np-SAD) based at ... London, has found that there has been a decline in ... to 1,372 in 2004, a drop of eight per cent. ... for the year 2004 reported by Coroners and Procurators Fiscal ...
Cached Biology News:California computer scientists double volume of data in NIH biotech repository 2California computer scientists double volume of data in NIH biotech repository 3California computer scientists double volume of data in NIH biotech repository 4Study shows big game hunters, not climate change, killed off sloths 2Study shows big game hunters, not climate change, killed off sloths 3Continued reduction in the number of drug-related deaths in the UK 2Continued reduction in the number of drug-related deaths in the UK 3
... Start up kit. Includes configured Laptop PC ... 2 MultiBlock satellite thermal cyclers (non-robotic). ... User friendly software. Store/track run data. ... lid. Outstanding uniformity. Advanced control ...
Glycerokinase; from Bacillus stearothermophilus...
A compact, high-speed single tube reader unit designed for benchtop 2D barcode reading. The unit can be used with all of ABgene's 2D barcoded tubes, including the 2ml CryoCode tube....
... Ascent FL is equipped ... luminometric measurement technologies that ... of advanced features of ... Ascent. Fluoroskan Ascent FL ...
Biology Products: